疾病领域
问源生物蛋白质组学解决方案可用于多种疾病治疗领域。
问源生物蛋白质组学解决方案可用于多种疾病治疗领域。
研究过程中纳入蛋白质组学数据，可深入揭示潜在生物学机理，加快推进感兴趣治疗领域研究进程，降低研究风险。无论您正在研究哪种疾病，问源生物的蛋白质组学解决方案都将为祝您一臂之力。
从基础研究到早期药物发现和临床试验，问源生物的蛋白质组解决方案可帮助洞悉癌症生物学分子机制，并揭示创新药物作用机制。
深入了解药物治疗或疾病发生发展过程中蛋白质组功能变化，可洞悉蛋白质组标志物，用于监测或预测治疗应答及治疗相关不良事件，降低药物开发失败风险。
问源生物的发现蛋白质组学平台，用于血浆/血清等液态样本，可获得高度可重复数据，是生物标志物研究的理想选择。
同时，在血浆/血清样本大规模临床研究中，结合靶向绝对定量蛋白质组学，可实现目标蛋白的稳定和可靠定量检测。
为更深入分析和探索低丰度蛋白质，我们进一步优化技术流程，去除血浆样本中高峰度蛋白，以解析样本中丰度较低的信号分子，提升可定量蛋白的可靠性。.
问源生物的蛋白质组学工作流程能够识别疾病相关异常调控蛋白，深刻洞见并揭示癌症生物学，识别进一步探新的生物标志物。问源生物的发现蛋白质组学，深入表征肿瘤FFPE切片中的非靶向蛋白质组，以揭示与疾病有关的蛋白质和通路，解析免疫治疗应答相关潜在生物标志物。结合靶向定量蛋白质组学，可用于抗体偶联药物靶点、免疫微环境检测，富集潜在获益患者和药物作用机制探索。
疾病动物模型组织或肿瘤样本蛋白质组学分析，帮助揭示治疗应答相关蛋白和通路。
Targeted protein degradation has recently emerged as a new frontier of medicine aimed at expanding the druggable proteome to develop and advance treatments for various diseases.
The success of these novel drug candidates depends on understanding how proteins are degraded and the effect of targeted degradation on the whole proteome. Our proprietary mass-spectrometry-based platforms uniquely address those needs and transform how novel protein degrader drugs are discovered and developed to reach the clinic today.
We perform your studies at our state-of-the-art facility, the largest high-end, GLP certified, and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research. This ensures data transferability and clinical trial success.
Biognosys’ TrueDiscovery™ platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity. It uniquely characterizes the degradation profile in early research phases, monitors protein turnover rates, and ultimately allows a better understanding and prioritization of the therapeutic modalities.
Biognosys’ TrueSignature™ platform exclusively offers customizable multiplexed proteomic panels for absolute quantification of up to 100 proteins in preclinical and clinical settings. It allows the monitoring of target engagement, pathway activation, pharmacodynamic, efficacy, and safety markers across the research and development phases.
Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications. The company's high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.
神经系统疾病药物开发成功率相对较低，更迫切需要理想的生物标志物，洞悉潜在生物学机制和药物靶点。
蛋白质组学可解析复杂的神经系统疾病发生发展分子机制，揭示潜在通路和新的治疗靶点。
由于缺乏对潜在生物过程和相关生物标志物的了解，阿尔茨海默病等神经退行性疾病的研究进程一度较慢。通过问源生物发现蛋白质组学工作流程，可深入表征阿尔茨海默氏症患者脑脊液样本（CSF）蛋白质组，筛选疾病发生发展相关蛋白和通路。
The recent success of immunotherapy has demonstrated the utility of harnessing the immune response for treating cancer and autoimmune disease. Deep quantitative proteomics offers the ability to go beyond known immunological markers and identify novel pathways and proteins that are implicated in the response to immunotherapy.
Immune cells are highly heterogeneous, requiring careful analysis at the level of
small
subsets or single cells. In this study, we used Biognosys’ Discovery Proteomics
to
provide a high-dimensional phenotypic characterization of sorted immune
cell
populations.
Going far beyond the known cell surface markers used in affinity-based
approaches,
we were able to identify thousands of novel proteins and pathways that
distinguish
specific immune cell subsets. This detailed proteomic data enables an
in-depth
analysis of the processes driving immune cell activation and suppression.
Proteomic profiling of tissue or tumor samples from animal models of disease
reveals
detailed information about the proteins and pathways involved in response to
therapy.
For example, Biognosys’ Discovery Proteomics was used to investigate the role
of
immune cell depletion in the response to PD-1 blockade in syngeneic mouse
models.
Biognosys’ drug Target Deconvolution approach Limited Proteomics
Mass Spectrometry (LiP-MS) can effectively identify protein drug
targets and characterize their binding properties in complex proteomes
without the need for compound modification or labeling.
In this specific example, LiP-MS was used to distinguish the specificity
and selectivity of different kinase and phosphatase inhibitors.
The LiP technology is a very valuable tool to identify target and offtarget of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.»
The unique molecular characteristics of rare diseases pose significant challenges for drug discovery. Proteomics tools such as mass spectrometry offer a versatile, reliable platform for deep phenotyping of genetic variants and uncovering previously unknown mechanisms of disease.
Gene editing tools such as CRISPR-Cas9 have revolutionized rare disease
research.
Highly targeted genetic modification allows high-throughput screening for
target
identification or validation, and rapid generation of cellular or animal
models.
Biognosys’ Discovery Proteomics profiling enables rapid and functional
validation of
targets in pre-clinical models, as well as the characterization of any
secondary
downstream consequences of gene modification.
Biognosys’ drug Target Deconvolution approach Limited Proteomics
Mass Spectrometry (LiP-MS) can effectively identify protein drug
targets and characterize their binding properties in complex proteomes
without the need for compound modification or labeling.
In this specific example, LiP-MS was used to distinguish the specificity
and selectivity of different kinase and phosphatase inhibitors.
The LiP technology is a very valuable tool to identify target and offtarget of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.»
慢性疾病，如心血管疾病和糖尿病，存在巨大的未满足医疗需求。
蛋白质组学加速可靠生物标志物的筛选和开发，进而改善慢性疾病诊断和治疗监测。围绕慢性疾病，问源生物的发现蛋白质组学技术平台，开发更安全、更精准的治疗方案。
血浆蛋白质组的全面、高通量分析能够全面分析个体健康状况。问源生物发现蛋白质组学平台，助力揭示肥胖、心血管、肝脏疾病和糖尿病相关生物标志物。
